You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 301 No. 7, February 18, 2009 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Medical News & Perspectives
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Topic Collections
 •Pain
 •Cardiovascular System
 •Rheumatology
 •Osteoporosis
 •Arrhythmias
 •Drug Therapy
 •Adverse Effects
 •Gastroenterology
 •Gastrointestinal Diseases
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Long-term Risks of Bisphosphonates Probed

Bridget M. Kuehn

JAMA. 2009;301(7):710-711.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A growing body of evidence suggests that long-term use of apopular class of drugs for osteoporosis and other bone disorders may be associated with the development of rare complications in some patients.

Bisphosphonate drugs, which stop the resorption of bone, are widely prescribed to treat such conditions as osteoporosis, Paget disease, and certain conditions in cancer patients. However, emerging data show a possible connection between long-term bisphosphonate use and some rare but serious adverse events, such as low-energy femoral fractures (caused by falls from a standing height or less) and osteonecrosis of the jaw. Additionally, a scientist at the US Food and Drug Administration (FDA) recently noted reports of esophageal cancer in patients taking alendronate.

Such reports add to the list of adverse effects already linked to bisphosphonates. In January 2008, the FDA alerted physicians that some patients taking these drugs may experience severe musculoskeletal pain within . . . [Full Text of this Article]

FEMORAL FRACTURES



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Flemingia macrophylla Extract Ameliorates Experimental Osteoporosis in Ovariectomized Rats
Ho et al.
Evid Based Complement Alternat Med 2009;0:nep179v1-nep179.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.